Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ViroLogic (VLGC) -- Ignore unavailable to you. Want to Upgrade?

To: Don Knowlton who wrote (2)	6/22/2000 12:23:00 AM
From: Ian@SI	Read Replies (1) \| Respond to of 59

Outstanding interview is available at on24.com with CEO. One of the topics covered is revenue potential for PhenoSense. e.g. - Cost of $700-900 / test depending upon how many drugs are being tested for resistance. US patient base is 350,000 [and growing]. Each patient requires about 1.5 tests per annum. Total market represents almost $0.5B for AIDS alone. current revenues are under $1M / qtr. Anyone think there's room for growth? ;-) Ian.